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Objective Procalcitonin (PCT) is a peptide that is found elevated in patients with sepsis
and severe infections. In healthy persons PCT serum levels are below 0.1 ng/mL. The aim
of this study was to investigate the value of serum PCT determination for risk evaluation
in patients with pneumonia.
Methods We focused on the correlation of PCT with the clinical status of the patient and
prognosis of the disease. In a prospective study, in a nonsurgical intensive care unit the
following parameters were assessed regularly in 93 patients with documented pneu-
monia: C-reactive protein (CRP), white blood cell count (WBC), body temperature, PCT
and Acute Physiology and Chronic Health Evaluation (APACHE) II score.
Results At the onset of infection 50% of the patients had elevated PCT levels above 2 ng/
mL. The model of multivariate analysis of all tested parameters on days 0–5 stratiﬁed for
clinical outcome (change in clinical classiﬁcation or death) showed local signiﬁcance for
APACHE II score only. None of the other parameters in this model serves as an isolated
indicator for change of clinical status or death. An intra-individual change of body
temperature or CRPwas never signiﬁcantly associated with a change in the clinical status
of the patient.
Conclusion Change in PCT on admission and at the end of the observation period
signiﬁcantly indicated a clinical change.
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INTRODUCTION
Hospital- and community-acquired infections are
associated with high morbidity, mortality and
increased hospital costs. In the EPIC study, the
most prevalent intensive care unit (ICU)-acquired
infection was pneumonia, accounting for 47% of
all infections. This was followed by other lower
respiratory tract infections (18%), urinary tract
infections (18%), bacteremia (12%) and wound
infections (7%) [1]. Accepted risk factors asso-
ciated with ICU-acquired infections include length
of ICU stay [2], antibiotic usage [3], neutropenia
[4], ventilation [1,5] and catheterization [6]. Stress
ulcer prophylaxis, use of steroids and the nutri-
tional status are also found to be linked with
nosocomially acquired pneumonia [1].
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For early and effective treatment consistent
diagnosis is essential. Clinical criteria include
fever, new or progressive pulmonary inﬁltrate
on X-rays, leukocytosis, recovery of a potential
pathogen in tracheal aspirate or blood cultures
[7]. However, none of these criteria is speciﬁc
for pneumonia. Pulmonary atelectasis, hemor-
rhage, infarction, or congestion, as well as drug
reactions, congestive heart failure or adult
respiratory distress syndrome (ARDS) may
show similar clinical signs [7,8]. The presence of
micro-organisms in a tracheobronchial specimen
may represent either colonization or infection.
Lung specimens drawn by protected specimen
brushing or bronchoalveolar lavage are most accu-
rate in the diagnosis of pneumonia, but are cost
intensive, require special skills and may often
lack the sensitivity to diagnose all cases of pneu-
monia or to rule out an infection [4,7]. Changes in
the plasma concentrations of C-reactive protein
(CRP) may turn out to be useful in identifying
patients with pneumonia, but are not speciﬁc
for pneumonia [9]. Thus not all patients are cor-
rectly diagnosed due to both over- and under-
diagnosis.
In recent studies procalcitonin (PCT), a peptide
consisting of 116 amino acids, was found to be
elevated in patients with sepsis and severe infec-
tions [10–12]. The concentrations of the prehor-
mone seemed closely related to the severity of the
bacterial infection. In healthy persons PCT serum
levels are below 0.1 ng/mL. Levels above 0.5 ng/
mL most likely indicate a severe bacterial infec-
tion [10,13]. After injection of bacterial endotoxin
high peak levels of serum PCT exceeding the base-
line levels (<0.1 ng/mL) by up to 1700-fold are
reported within 24 h in healthy volunteers. In the
same study, PCT concentrations were closely
related to serum tumor necrosis factor-a and inter-
leukin-6 levels [14]. However, the position of PCT
in the pathophysiology of sepsis and its relation
to tumor necrosis factor-a, interleukin-6 and other
cytokines detected in severe infections is, as
yet, unclear. Previous studies have shown that
PCT may be a valuable parameter in severe infec-
tions of neutropenic patients [12,13]. The role of
PCT in the diagnosis of severe infections is well
established, but there are few data concerning
its prognostic properties [15]. The aim of this
study was to investigate the use of serum PCT
determination for risk evaluation in patients with
pneumonia.
PATIENTS AND METHODS
A prospective study was carried out between
August 1997 and March 1998 in the nonsurgical
ICU of the hospital Neuko¨lln Berlin. Ethylenedia-
minetetraacetic acid (EDTA) blood samples were
drawn from all patients in whom infection was
suspected, and were stored prospectively for the
determination of PCT. Patients were graded daily
according to the Consensus Conference recom-
mendations for having Systematic Inﬂamatory
Response Syndrome, sepsis, severe sepsis or septic
shock [16]. The progression in the clinical status
according to these deﬁnitions was recorded as
‘change’. The following parameters were recorded
for all patients: demographic data, underlying
disease, microbiology, assisted ventilation, CRP,
leukocyte count and temperature. The Acute
Physiology and Chronic Health Evaluation
(APACHE) II score was determined daily [17].
All patients were seen daily by the senior author.
PCT was determined in all patients who were
clinically judged to develop pneumonia according
to the Center for Disease Control guidelines
[18]. Day 0 on Figures 1–3 is the day of onset of
pneumonia. PCT levels were determined using
antibody-coated tubes provided by Brahms
Diagnostica (Berlin, Germany) as a complete diag-
nostic-kit (LUMI test Pro-Calcitonin) in a Lumin-
ometer (Behring Diagnostika, Marburg, Germany)
[10]. The samples were stored at 70 8C until
processing. All samples were processed as double
measurements directly following the calibration
of the standard curve by provided standards.
CRP (normal value: <5mg/L) was measured by
Figure 1 Box-plot of body temperature (8C) in surviving
and nonsurviving patients with pneumonia; day 0¼ onset
of clinical signs of infections.
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nephelometry (Behring Diagnostics, Marburg,
Germany).
Statistical evaluation
Two criteria were assessed as clinical ‘outcome’
variables. (1) Patients were evaluated for change in
SIRS classiﬁcation as described by Rangel-Frausto
et al. [16]. (2) The mortality of the patients was
assessed and clinically graded as attributable
death. Both criteria were evaluated separately.
Although continuous parameters were assessed
on a daily basis, measurements were not available
for every day and patient. To overcome the
resulting pattern of missing values we decided
to aggregate the measurements by computation
of 3-day maximum values derived for days 0–2, 3–
5 and so on, where day 0 denotes the day of entry
into the longitudinal observation. Data description
and statistical inference are based on these 3-day
maxima aggregates. All the calculations were
repeated using a 3-day average, but the results
are omitted here because they showed nearly the
same statistical results. Note that we decided to
use maximum values instead of 3-day median
values to retain the ‘immediate signal’ inﬂuence
of single increased values. If only one of three PCT
assessments is increased, the 3-day maximumwill
be remarkably increased accordingly, whereas the
3-day median will remain (conservatively) robust
concerning this single outlier of interest. There-
fore, the intra-individual 3-day maximum can be
regarded as a surrogate measure, which allows
both the signal property of a single increase in
clinical parameters to be retained and the missing
value pattern in the original data to be overcome.
Data description is primarily based on medians
and 5 and 95% quartiles to both overcome and
illustrate the inﬂuence of single outlier values in
interindividual analyses. Graphical representation
is based on nonparametric box plots, additionally
providing the 25 and 75% quartiles of the 3-day
maxima. The intra-individual differences and
ratios of subsequent 3-day maxima were consid-
ered next, to illustrate the dynamics in parameter
changes during clinical observations. We com-
pared the two groups of patients with and without
occurrence of clinically relevant outcome or
change concerning the dynamics in the above
clinical parameters. Group comparisons were
drawn out by applying two-sampleWilcoxon tests
[19] to the intra-individual parameter ratios from
one 3-day maximum to the next. Furthermore, we
applied two-sample log rank tests to include the
information on time under observation until
occurrence of clinically relevant outcome.
Corresponding multivariate analysis was based
on multiple proportional hazards regression mod-
els (involving the information on survival times)
[20], where the following models were speciﬁed,
respectively:
1. inﬂuence of theﬁrst 3-daymaxima (days 0–2) for
temperature, white blood cell count (WBC),
APACHE II, PCT; and
2. inﬂuence of the subsequent correspondingmax-
ima (days 3–5).
Results of these multivariate analyses are
expressed using Wald tests (as an indication of
Figure 2 Box-plot of white blood cell count (WBC) (cells/
nL) in surviving and nonsurviving patients with pneumo-
nia; day 0¼ onset of clinical signs of infections.
Figure 3 Box-plot of body APACHE II scores in surviving
and nonsurviving patients with pneumonia; day 0¼ onset
of clinical signs of infections.
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local signiﬁcance) and the corresponding risk ratio
or hazard ratio estimates (as an illustration of
possible clinical relevance of statistically signiﬁ-
cant effects).
All computations were performed using SAS
(Release 6.12 for Windows), box plots were gen-
erated using SPSS (Version 6.13 for Windows).
RESULTS
Ninety-three of a total of 205 patients were diag-
nosed with pneumonia. In 37 (40%) cases pneu-
monia was acquired nosocomially, in 43 (46%)
pneumonia was community acquired. Thirteen
(14%) of the patients had aspiration pneumonia,
lung abscess, or other type of infectious lung dis-
ease. Patients were observed for a mean of 20 days
(range 2–110 days) and had a mortality of 33%. At
the time of onset of signs of infection, 72% of the
patients were on assisted ventilation.
Distribution of the data
The distribution of the parameters of the entire
population using the 5, 50 and 95% percentiles is
described in Table 1. Total number of assessable
patients at the 3-day time points were n¼ 93 at day
0–2; n¼ 77 at day 3–5; n¼ 62 at day 6–8; n¼ 47 at
day 9–11; and n¼ 34 at day 12–14. It was obvious
that all the parameters showed large variations.
The mean temperature did not decrease over the
course of the observation. Nor was there a marked
change in the median WBC and APACHE II
scores, whereas median CRP values decreased
from 18.35mg/dL to upper normal values, show-
ing a very wide distribution. Nearly 50% of the
PCT values at the onset of infection were below
2ng/mL, however, there were outliers >60 ng/
mL. The distribution ranged from 0.2 to 258 ng/
mL at the start of the observation.
Prognostic impact of the parameters
To elucidate the prognostic value of the para-
meters tested, patients who survived were com-
pared with those who died during their stay in
ICU. Themaxima of 3 subsequent dayswere tested
for differences. Signiﬁcantly different groups are
marked by a star. As shown in the box plot in
Figure 1, there was no difference in the tempera-
tures of patients who died and those who sur-
vived. However, patients who did not survive
tended to show lower temperatures in the later
course of the observation. Figure 2 shows that
WBC after day 6–8 was signiﬁcantly higher in
nonsurvivors. As illustrated in Figure 3, the
APACHE II score was signiﬁcantly higher at every
point in patients who died. CRP did not show
signiﬁcant differences in either group (Figure 4).
The box plot of PCT, shown in Figure 5, illustrates
a skewed distribution in both groups with values
high above themedian. After day 3–5 patients who
did not survive had signiﬁcantly higher PCT
values than those who survived.
The values of the parameters for survivors ver-
sus nonsurvivors on onset of infection (day 0–2)
were compared using the two-sample log rank test
to involve the time until death to give the follow-
ing cut-off points: 38.5 8C for temperature, 9 cells/
nL forWBC, a score of 15 for APACHE II, 8mg/dL
Table 1 Distribution (5 and 95% percentiles and median)
of temperature, white blood cell count (WBC), APACHE II
score, C-reactive protein (CRP) and procalcitonin (PCT), in
the entire population
Day 5% Median 95%
Temperature (8C)
0–2 36.9 38.6 39.6
3–5 36.1 38.0 39.6
6–8 36.8 38.2 39.2
9–11 35.2 38.0 39.7
12–14 35.5 37.6 39.6
WBC (cells/nL)]
0–2 3 13.2 30.6
3–5 6.5 11.4 29.9
6–8 7.4 12.8 30.4
9–11 9.3 15.5 48.9
12–14 6.9 15.0 79.8
APACHE II
0–2 9.0 21.5 37.0
3–5 7.7 19.0 30.7
6–8 10.3 18.0 32.3
9–11 10.0 18.5 36.0
12–14 8.5 19.7 41.0
CRP (mg/dL)
0–2 4.30 18.35 45.40
3–5 2.60 17.50 43.20
6–8 2.1 10.90 43.60
9–11 2.1 14.10 42.30
12–14 0.65 10.50 37.00
PCT (ng/mL)
0–2 0.2 2.3 59.3
3–5 0.2 1.1 38.9
6–8 0.2 0.8 25.0
9–11 0.2 0.7 6.3
12–14 0.2 0.7 8.4
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for CRP and 2ng/mL for PCT. Elevation of the
parameters was never signiﬁcantly associated
with a shorter time until death.
Dynamics in parameter changes
To investigate the dynamics in parameter change,
the intra-individual ratios of the subsequent 3-day
maxima were calculated. Patients were grouped
for change in SIRS classiﬁcation representing a
worsening of the clinical status, presuming that
a change in SIRS classiﬁcation of the patient goes
together with a change of the observed para-
meters. Table 2 shows the examples of the paired
Wilcoxon test for signiﬁcant differences of the
ratios in patients with a change in their clinical
status and those without. A change in the tem-
perature and CRP concentration in subsequent 3-
day maxima was never signiﬁcantly associated
with a change in the clinical status of the patient.
During the second half of the observation period a
change in the APACHE II score was associated
with a worsening of the clinical status at a highly
signiﬁcant level. The ratio of the WBC on day 6–8
to that on day 3–5 showed signiﬁcant differences
between these two groups. Changes in PCT values
between admission and the end of the observation
period were also signiﬁcantly different concerning
a change of the clinical status of the patient.
Multivariate analysis
Multivariate results of all tested parameters of
days 0–2 and 3–5 on clinically relevant outcome
are given in Table 3. The corresponding results for
a change in the clinical status of the patient are
given in Table 4. Only the APACHE II score
showed local signiﬁcance indicating a change or
death in this model. However the risk ratio of 1.1
Figure 4 Box-plot of C-reactive protein (CRP) serum
concentrations (mg/dL) in surviving and nonsurviving
patients with pneumonia; day 0¼ onset of clinical signs of
infections.
Figure 5 Box-plot of procalcitonin (PCT; ng/mL) in
surviving and nonsurviving patients with pneumonia;
day 0¼ onset of clinical signs of infections.
Table 2 Intra-individual ratios of subsequent 3-day max-
ima of temperature, white blood cell count (WBC),
APACHE II score, C-reactive protein (CRP) and procalci-
tonin (PCT) stratified for the occurrence of clinical change
of the patient’s status
Ratio P-value
Temperature Day 3–5 : day 0–2 0.32
Day 6–8 : day 3–5 0.88
Day 9–11 : day 6–8 0.76
Day 12–14 : day 9–11 0.52
WBC Day 3–5 : day 0–2 0.89
Day 6–8 : day 3–5 0.03
Day 9–11 : day 6–8 0.53
Day 12–14 : day 9–11 0.87
APACHE II Day 3–5 : day 0–2 0.24
Day 6–8 : day 3–5 0.24
Day 9–11 : day 6–8 <0.01
Day 12–14 : day 9–11 <0.01
CRP Day 3–5 : day 0–2 0.66
Day 6–8 : day 3–5 0.57
Day 9–11 : day 6–8 0.51
Day 12–14 : day 9–11 0.79
PCT Day 3–5 : day 0–2 0.03
Day 6–8 : day 3–5 0.77
Day 9–11 : day 6–8 0.21
Day 12–14 : day 9–11 0.06
P-values not adjusted for multiplicity.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 93–100
Brunkhorst et al Risk evaluation in severe pneumonia 97
indicates a low clinical signiﬁcance. This is also
reﬂected by the longitudinal analysis of the iso-
lated parameters (day 0–15), demonstrating that
none of the parameters was able to give signiﬁcant,
time-dependent signals for clinical change or out-
come (data not shown). None of the parameters in
either model serves as an isolated indicator for
change in clinical status or death.
DISCUSSION
In our study in patients with pneumonia, no iso-
lated clinical or laboratory parameter was able to
serve as a sensitive indicator of the prognosis of a
patient at the onset of clinical signs of infection.
Body temperature on admission was not a useful
predictor of outcome. Even a change in tempera-
ture was not a risk factor for worsening clinical
status. This conﬁrms recent data showing a sensi-
tivity of only 53% for body temperature over
38.5 8C in diagnosis of sepsis [21]. It should be
noted that there is a trend, without statistical
signiﬁcance, of lower body temperature in patients
who did not survive. Elevated WBC is one of the
basic parameters that in earlier studies showed
better sensitivity (73%) than body temperature
[21]. This agrees with our ﬁndings, that in the later
course of pneumonia WBC is increased in patients
who did not survive. In the multivariate analysis,
temperature and WBC have no prognostic rele-
vance. APACHE II is a clinical score of the
patient’s status and our study conﬁrms that it
indicates a risk of worsening clinical condition
[22]. In the multivariate analysis it was the only
statistically signiﬁcant risk factor for change in
diagnosis, especially in the later course of pneu-
monia. A score involving the acute physiology is
more likely to be associatedwith clinical status and
outcome. It should be kept in mind that due to the
3-day aggregation used in this study, longer ‘avail-
able’ clinical parameters may be overestimated,
whereas short peaks of laboratory values may be
‘missed’. Also, only clinical status, outcome and
change in diagnosis were studied. However, ICU
patients with pneumonia often suffer from under-
lying diseases which may cause a change in their
clinical status without correlation to pneumonia or
infection. In this study, seven of the 31 patients
who died had complications of their underlying
disease, which was not itself directly related to
pneumonia. In these cases, the APACHE II score
better reﬂects the clinical status of the patient
without being speciﬁc for severity of infection.
Moreover PCT, in contrast to CRP, WBC and
temperature, has been shown to be very speciﬁc
for infections indicating the severity of the inﬂam-
mation [8, 23].
Elevated CRP concentrations were not prognos-
tic. Nor were the dynamics of this parameter sig-
niﬁcantly associated with clinical change in the
patient. This contrasts with data where CRP alone
is used for monitoring patients with sepsis in ICU
[24] and conﬁrms data on the critical interpretation
of CRP values [24–26].
The determination of PCT has a slight, but
limited, prognostic value in the present study. In
the later course of the disease, nonsurvivors seem
to show higher levels of PCT. This is also reported
Table 3 Multivariate analysis of subsequent 3-day maxima
of temperature, white blood cell count (WBC), APACHE II
score, C-reactive protein (CRP) and procalcitonin (PCT) as
a risk factor for nonsurvival
Day P-value Risk ratio
0–2 Temperature 0.402 0.8
WBC 0.124 1.0
APACHE II 0.001 1.1
CRP 0.133 0.9
PCT 0.222 0.9
3–5 Temperature 0.510 1.2
WBC 0.272 1.0
APACHE II 0.017 1.1
CRP 0.258 1.0
PCT 0.545 1.0
P-values not adjusted for multiplicity; risk ratio obtained
from multiple hazards regression.
Table 4 Multivariate analysis of subsequent 3-day maxima
of temperature, white blood cell count (WBC), APACHE II
score, C-reactive protein (CRP) and procalcitonin (PCT) as
a risk factor for clinical change in the patient’s status
Day P-value Risk ratio
0–2 Temperature 0.298 0.8
WBC 0.482 1.0
APACHE II 0.006 1.1
CRP 0.989 1.0
PCT 0.059 1.0
3–5 Temperature 0.914 1.0
WBC 0.818 1.0
APACHE II 0.012 1.1
CRP 0.967 1.0
PCT 0.242 1.0
P-values not adjusted for multiplicity; risk ratio obtained
from multiple hazards regression.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 93–100
98 Clinical Microbiology and Infection, Volume 8 Number 2, February 2002
in an animal experiment where administration of
exogenous PCT to septic hamsters signiﬁcantly
increased mortality [27]. The dynamics of the
parameter seem to indicate a change in the clinical
status of the patient. However, large intra-indivi-
dual differences require further investigation. In a
study of community-acquired pneumonia PCT
was elevated in caseswith classical bacterial aetiol-
ogy rather than in cases caused by atypical organ-
isms [26]. Another study in febrile nonshock
patients found that PCT values determined on
admission helped to identify patients who were
at risk of mortality [28]. Recent data comparing
CRP and PCT [25,26,29], indicate an advantage of
PCT in the diagnosis and monitoring of infections
as seen in our study. The available data suggest
that in neonates with severe infections PCT levels
rise more rapidly than CRP levels, so the PCT
sensitivity is higher [30]. The lack of correlation
between the CRP and PCT values in this study
indicates a different pathophysiological mechan-
ism for the two parameters. CRP is known to be
inﬂuenced by interleukin-6 and tumor necrosis
factor-a [31], whereas the role of PCT in the inﬂam-
matory process is as yet unknown. The position of
PCT in the management of infectious diseases
needs to be elucidated in further studies.
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